SCYNEXIS Begins Phase 1 Trial for SCY-770, a Novel ADPKD Therapy
SCYX is trading near its 52-week low of $3.68 (6.0% above the low) on light trading volume (0.4× avg).
Summary
SCYNEXIS has initiated a Phase 1 clinical study for SCY-770, a novel AMPK activator, targeting Autosomal Dominant Polycystic Kidney Disease (ADPKD). This marks a key development for the company's pipeline, following its recent acquisition of SCY-770 and a period of financial restructuring including a reverse stock split. Advancing this drug, which has Orphan Drug Designation and prior safety data, is crucial for a small biotech focused on rare diseases. Topline data from this Phase 1 study are expected in Q3 2026, with Phase 2 initiation planned for Q4 2026.
At the time of this announcement, SCYX was trading at $3.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $38.4M. The 52-week trading range was $3.68 to $10.48. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.